Shares of Cidara Therapeutics Inc. (NASDAQ:CDTX) have been given an average rating of “Hold” by the seven research firms that are currently covering the company. Two investment analysts have rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $18.17.

A number of brokerages recently weighed in on CDTX. WBB Securities downgraded shares of Cidara Therapeutics from a “hold” rating to a “sell” rating and set a $10.50 price target on the stock. in a research report on Friday, September 23rd. Wedbush reiterated an “outperform” rating on shares of Cidara Therapeutics in a research report on Tuesday, August 16th. Needham & Company LLC reiterated a “buy” rating and issued a $20.00 price target on shares of Cidara Therapeutics in a research report on Monday, August 15th. BTIG Research reiterated a “buy” rating and issued a $24.00 price target on shares of Cidara Therapeutics in a research report on Monday, August 15th. Finally, Zacks Investment Research downgraded shares of Cidara Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 22nd.

Cidara Therapeutics (NASDAQ:CDTX) remained flat at $10.06 during mid-day trading on Wednesday. The company had a trading volume of 41,714 shares. The company has a 50-day moving average price of $11.37 and a 200-day moving average price of $11.75. The stock’s market cap is $139.89 million. Cidara Therapeutics has a one year low of $9.48 and a one year high of $18.07.

Cidara Therapeutics (NASDAQ:CDTX) last announced its quarterly earnings results on Thursday, August 11th. The biotechnology company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by $0.09. On average, equities analysts expect that Cidara Therapeutics will post ($3.35) EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of CDTX. TFS Capital LLC acquired a new position in shares of Cidara Therapeutics during the second quarter valued at $217,000. BlackRock Institutional Trust Company N.A. boosted its position in shares of Cidara Therapeutics by 109.9% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 72,259 shares of the biotechnology company’s stock valued at $745,000 after buying an additional 37,830 shares in the last quarter. BlackRock Fund Advisors boosted its position in shares of Cidara Therapeutics by 123.6% in the second quarter. BlackRock Fund Advisors now owns 275,247 shares of the biotechnology company’s stock valued at $2,838,000 after buying an additional 152,122 shares in the last quarter. BlackRock Investment Management LLC boosted its position in shares of Cidara Therapeutics by 150.0% in the second quarter. BlackRock Investment Management LLC now owns 43,179 shares of the biotechnology company’s stock valued at $445,000 after buying an additional 25,907 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Cidara Therapeutics by 6.2% in the second quarter. Vanguard Group Inc. now owns 172,233 shares of the biotechnology company’s stock valued at $1,776,000 after buying an additional 9,981 shares in the last quarter. 58.87% of the stock is owned by institutional investors.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

5 Day Chart for NASDAQ:CDTX

Receive News & Stock Ratings for Cidara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc. and related stocks with our FREE daily email newsletter.